Keisuke Kirita

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 785 citations

Cancer Immunosurveillance, Autoimmune Disease, T-regulatory Cell +12

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 150 citations

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden

Tomoyuki Naito, Hibiki Udagawa, Shigeki Umemura et al. · Lung Cancer · 2019 · 100 citations

Oncology, Medicine, Swi/snf Complex +12

Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report

Tomoyuki Naito, Shigeki Umemura, Hiroshi Nakamura et al. · Thoracic Cancer · 2019 · 96 citations · Full text